Myriad Genetics (MYGN) Inventory (2011 - 2026)

Myriad Genetics has disclosed Inventory across 16 years of filings, most recently posting $27.9 million for Q1 2026.

• In Q1 2026, Inventory fell 1.41% year-over-year to $27.9 million; the TTM figure through Mar 2026 stood at $27.9 million (down 1.41% YoY), while the FY2025 annual figure was $30.6 million, up 11.27% from the prior year.
• Inventory eased to $27.9 million in Q1 2026, from $30.6 million in the prior quarter.
• Over the last five years, Inventory for MYGN reached as high as $31.6 million in Q3 2025 and fell as low as $15.4 million in Q2 2022.
• The 5-year median for Inventory is $25.1 million (2023), against an average of $24.3 million.
• Annual changes were most pronounced in 2022 — Inventory sank 36.59% — and 2023, when it soared 46.1%.
• A 5-year view of Inventory shows it stood at $20.1 million in 2022, then advanced by 9.45% to $22.0 million in 2023, then advanced by 25.0% to $27.5 million in 2024, then advanced by 11.27% to $30.6 million in 2025, then declined by 8.82% to $27.9 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $27.9 million, $30.6 million, and $31.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.